ZA939271B - Pyrrolopyrimidines - Google Patents

Pyrrolopyrimidines

Info

Publication number
ZA939271B
ZA939271B ZA939271A ZA939271A ZA939271B ZA 939271 B ZA939271 B ZA 939271B ZA 939271 A ZA939271 A ZA 939271A ZA 939271 A ZA939271 A ZA 939271A ZA 939271 B ZA939271 B ZA 939271B
Authority
ZA
South Africa
Prior art keywords
stress
compounds
treatment
pyrrolopyrimidines
formulawherein
Prior art date
Application number
ZA939271A
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA939271B publication Critical patent/ZA939271B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA939271A 1992-12-17 1993-12-10 Pyrrolopyrimidines ZA939271B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99176492A 1992-12-17 1992-12-17

Publications (1)

Publication Number Publication Date
ZA939271B true ZA939271B (en) 1995-06-12

Family

ID=25537532

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA939271A ZA939271B (en) 1992-12-17 1993-12-10 Pyrrolopyrimidines

Country Status (24)

Country Link
US (1) US6765008B1 (fr)
EP (1) EP0674641B1 (fr)
JP (1) JP2895961B2 (fr)
KR (2) KR0173172B1 (fr)
CN (1) CN1038131C (fr)
AT (1) ATE177101T1 (fr)
BR (1) BR9307646A (fr)
CA (1) CA2150016C (fr)
CZ (1) CZ286892B6 (fr)
DE (1) DE69323768T2 (fr)
DK (1) DK0674641T3 (fr)
ES (1) ES2128544T3 (fr)
FI (2) FI935585A (fr)
GR (1) GR3029561T3 (fr)
HU (3) HU0103927D0 (fr)
IL (5) IL119461A (fr)
MY (1) MY131458A (fr)
NO (1) NO306678B1 (fr)
NZ (1) NZ258690A (fr)
PL (1) PL176526B1 (fr)
RU (1) RU2124015C1 (fr)
TW (1) TW295585B (fr)
WO (1) WO1994013676A1 (fr)
ZA (1) ZA939271B (fr)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
EP0723533A1 (fr) * 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyle-n-arylpyrimidinamines et leurs derives
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
US5854232A (en) * 1994-04-29 1998-12-29 Pfizer Inc. Acyclic anc cyclic amides as neurotransmitter release enhancers
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
EP0765327B1 (fr) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo et pyrrolopyridines
EP0729758A3 (fr) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies
US5644057A (en) * 1995-05-12 1997-07-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US5804685A (en) * 1995-06-07 1998-09-08 Neurogen Corporation Deazapurine derivatives: a new class of CRF1 specific ligands
ATE182148T1 (de) * 1995-05-12 1999-07-15 Neurogen Corp Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
MX9709867A (es) * 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
AU738304B2 (en) * 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
US5955613A (en) * 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
DK0778277T3 (da) * 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
PT882051E (pt) * 1996-02-07 2002-04-29 Janssen Pharmaceutica Nv Tiofenopirimidinas
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
NZ331647A (en) * 1996-03-26 2000-03-27 Du Pont Pharm Co Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
ATE228518T1 (de) * 1996-06-06 2002-12-15 Otsuka Pharma Co Ltd Amid derivate
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
DK0915880T3 (da) * 1996-07-24 2008-02-11 Bristol Myers Squibb Pharma Co Azolotriaziner og pyrimidiner
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
DK0920429T3 (da) * 1996-08-06 2003-05-12 Pfizer Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
US5861398A (en) * 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
AU4270297A (en) * 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
US6413971B1 (en) 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
EP0970082A2 (fr) 1997-02-18 2000-01-12 Neurocrine Biosciences, Inc. Antagonistes crf biazacycliques
US5972945A (en) * 1997-06-13 1999-10-26 Neurogen Corporation 2-aminoalkylaminoquinolines; dopamine receptor subtype specific ligands
US6313141B1 (en) 1997-06-13 2001-11-06 Neurogen Corporation 2-aminoalkylaminoquinolines as dopamine D4 ligands
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO1999045007A1 (fr) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Pyrazolo[4,3-b]pyridines antagonistes du facteur de liberation de la corticotropine (crf)
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
AU3375999A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino(2,3-b)indole and 5,6,7,8-tetrahydro-9h-pyrimidino(4,5-b)indole derivatives: crf1 specific ligands
EP1068207A1 (fr) * 1998-04-02 2001-01-17 Neurogen Corporation DERIVES AMINOALKYLE SUBSTITUES DE 9H-PYRIDINO 2,3-b]INDOLE ET 9H-PYRIMIDINO 4,5-b]INDOLE
US6147085A (en) * 1999-04-01 2000-11-14 Neurogen Corporation Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives
WO1999051599A1 (fr) * 1998-04-02 1999-10-14 Neurogen Corporation Derives aminoalkyle substitues de pyrrolo[2,3-b]pyridine et pyrrolo[2,3-d]pyrimidine: modulateurs de recepteurs de crf1
US6221875B1 (en) 1998-04-02 2001-04-24 Neurogen Corporation Substituted 9H-pyridino [2,3-B]indole and 9H-pyrimidino [4,5-B]indole derivatives: selective neuropeptide Y receptor ligands
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
AR020590A1 (es) * 1998-06-02 2002-05-22 Cadus Pharmaceutical Corp 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden
WO1999064422A1 (fr) 1998-06-09 1999-12-16 Neurogen Corporation Derives de pyrido[2, 3-b]indolizine et analogues aza associes; ligands crf1 specifiques
WO2000027850A2 (fr) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et methodes associees
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
PT1129091E (pt) 1998-11-12 2003-02-28 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos relacionados
EP1176146B1 (fr) 1999-03-11 2005-06-08 Taisho Pharmaceutical Co., Ltd Derives de carbamoyl tetrahydropyridine
EP1040831A3 (fr) 1999-04-02 2003-05-02 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
EA200200424A1 (ru) 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
EA200200688A1 (ru) * 2000-01-18 2003-02-27 Пфайзер Продактс Инк. Антагонисты фактора, высвобождающего кортикотропин
AU2001232271A1 (en) * 2000-02-14 2001-08-20 Japan Tobacco Inc. Preventives/remedies for postoperative stress
US6613901B2 (en) 2000-03-08 2003-09-02 Neurogen Corporation 2-aminoalkylaminoquinolines as dopamine D4 ligands
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CN1263757C (zh) * 2000-12-01 2006-07-12 Osi制药公司 特异于腺苷a1,a2a和a3受体的化合物及其应用
KR100897430B1 (ko) * 2000-12-01 2009-05-14 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ₁, ａ₂ａ 및 ａ₃ 수용체에 특이적인 화합물및 그의 용도
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
RU2308457C2 (ru) 2001-04-27 2007-10-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Пиразоло [1, 5-а] пиридины и содержащие их лекарственные средства
EP1392309B1 (fr) 2001-05-14 2007-01-17 Bristol-Myers Squibb Company Pyrazinones, pyridines et pyrimidines substitues en tant que ligands de la corticoliberine
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
AU2002360436A1 (en) 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
DE60236458D1 (de) 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
TWI283679B (en) 2002-10-22 2007-07-11 Eisai Co Ltd 7-phenylpyrazolopyridine compounds
GR1004664B (en) * 2002-11-26 2004-09-02 Bionature E A Ltd The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references
WO2004054566A1 (fr) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Derives de pregabalin pour le traitement de la fibromyalgie et d'autres troubles
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
WO2004064748A2 (fr) * 2003-01-21 2004-08-05 Trustees Of Dartmouth College Compositions et procedes destines au traitement du cancer de l'ovaire
WO2004092170A2 (fr) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines et pyrazolotriazines et leurs procedes de fabrication et d'utilisation
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
WO2004092177A1 (fr) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2552503C (fr) 2004-01-06 2011-09-13 Taisho Pharmaceutical Co., Ltd. Derives de pyrrolopyrimidine et de pyrrolotriazine
WO2005066182A1 (fr) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Derives de thienopyrimidine et de thienopyridine substitues par un groupe amino cyclique
EP1725562A1 (fr) * 2004-03-05 2006-11-29 Taisho Pharmaceutical Co., Ltd D riv s pyrrolopyrimidine
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
JP2007161585A (ja) * 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
WO2006116218A1 (fr) * 2005-04-22 2006-11-02 Wyeth Formes cristallines de {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}chlorhydrate amine
TW200719886A (en) * 2005-04-22 2007-06-01 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
JP2008538572A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
CA2644662A1 (fr) * 2006-03-24 2007-10-04 Wyeth Nouvelles combinaisons therapeutiques pour le traitement de la depression
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
US8030304B2 (en) 2006-09-20 2011-10-04 Eli Lilly And Company Thiazole pyrazolopyrimidines CRF1 receptor antagonists
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2522351B1 (fr) * 2007-06-13 2017-09-06 Research Development Foundation Traitement et prévention de tauopathies et de l'amyloïdose de bêta-amyloïde en modulant la signalisation de récepteur CRF
WO2009104080A2 (fr) 2008-02-20 2009-08-27 Targia Pharmaceuticals Compositions pharmaceutiques actives sur le snc et méthodes d'utilisation
NZ588376A (en) 2008-04-15 2011-06-30 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound having antagonism against corticotropin-releasing factor (CRF) receptor
WO2009128057A2 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
WO2010066629A2 (fr) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Nouvelles azaindoles
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
TR201902525T4 (tr) 2013-02-22 2019-03-21 Pfizer Janus ile alakalı kinazların (jak) inhibitörleri olarak bir veya daha fazla ilave ajan ile pirolo [2,3-d]pirimidin türevlerinin kombinasyonu.
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
US10344032B2 (en) 2014-09-17 2019-07-09 Pécsi Tudományegyetem Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders
MX2018000880A (es) 2015-07-20 2018-08-24 Genzyme Corp Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
IL314404A (en) * 2016-11-18 2024-09-01 Cystic Fibrosis Found Pyrrolopyrimidines as CFTR enhancers
KR20230043222A (ko) 2020-08-12 2023-03-30 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
EP4267573A1 (fr) 2020-12-23 2023-11-01 Genzyme Corporation Inhibiteurs deutérés du récepteur du facteur 1 de stimulation des colonies (csp-1r)
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2818676A1 (de) * 1978-04-27 1979-11-08 Troponwerke Gmbh & Co Kg Substituierte 5,6-dimethylpyrrolo 2,3-d pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3145287A1 (de) * 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5002950A (en) * 1986-10-24 1991-03-26 Warner-Lambert Co. 7-deazaguanines as immunomodulators
US5153352A (en) 1988-10-25 1992-10-06 Bristol-Myers Squibb Company Process for preparation of intermediates of carbocyclic nucleoside analogs
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
AU647822B2 (en) * 1990-09-14 1994-03-31 Marion Merrell Dow Inc. Novel carbocyclic adenosine analogs useful as immunosuppressants
GB9022644D0 (en) 1990-10-18 1990-11-28 Ici Plc Heterocyclic compounds
DE59303950D1 (de) 1992-08-10 1996-10-31 Volkswagen Ag Schalteinrichtung für ein Getriebe

Also Published As

Publication number Publication date
IL119461A0 (en) 1997-01-10
TW295585B (fr) 1997-01-11
HU0103927D0 (en) 2001-12-28
FI109799B (fi) 2002-10-15
RU95113862A (ru) 1997-06-10
HU225053B1 (en) 2006-05-29
KR19990067704A (ko) 1999-08-25
PL176526B1 (pl) 1999-06-30
HU9303515D0 (en) 1994-04-28
RU2124015C1 (ru) 1998-12-27
CA2150016C (fr) 2000-02-08
WO1994013676A1 (fr) 1994-06-23
IL119462A0 (en) 1997-01-10
CZ158495A3 (en) 1996-01-17
US6765008B1 (en) 2004-07-20
PL309357A1 (en) 1995-10-02
IL119461A (en) 2000-02-29
CN1038131C (zh) 1998-04-22
NO952398D0 (no) 1995-06-16
GR3029561T3 (en) 1999-06-30
NO306678B1 (no) 1999-12-06
JP2895961B2 (ja) 1999-05-31
JPH07509726A (ja) 1995-10-26
IL119462A (en) 2000-02-29
HU221587B (hu) 2002-11-28
NZ258690A (en) 1997-01-29
FI935585A (fi) 1994-06-18
AU690090B2 (en) 1998-04-23
CN1097758A (zh) 1995-01-25
AU5666494A (en) 1994-07-04
EP0674641A1 (fr) 1995-10-04
KR950704320A (ko) 1995-11-17
DE69323768T2 (de) 1999-07-01
ATE177101T1 (de) 1999-03-15
KR0173172B1 (ko) 1999-02-01
MY131458A (en) 2007-08-30
NO952398L (no) 1995-06-16
IL107897A0 (en) 1994-04-12
FI935585A0 (fi) 1993-12-13
BR9307646A (pt) 1999-05-25
HUT70505A (en) 1995-10-30
IL107897A (en) 2001-01-28
DK0674641T3 (da) 1999-09-27
CA2150016A1 (fr) 1994-06-23
EP0674641B1 (fr) 1999-03-03
DE69323768D1 (de) 1999-04-08
FI20000343A (fi) 2000-02-16
ES2128544T3 (es) 1999-05-16
CZ286892B6 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
ZA939271B (en) Pyrrolopyrimidines
MY131382A (en) Pyrazoles and pyrazolopyrimidines
GR3031166T3 (en) Pyrazolo and pyrrolopyridines
MY109002A (en) Amino-substituted pyrrazoles.
ZA954921B (en) Methods of administering crf antagonists
MY115300A (en) Pyrazolopyrimidines.
GB9317104D0 (en) Therapeutic heterocycles
HK1002765A1 (en) Use of binding agents to cd23 in the treatment of autoimmune diseases